CTI BioPharma Investor
CTI BioPharma is a company that focuses on developing and selling cancer treatment products. One of its main products in development is Pixantrone, which is currently in phase III trials and is intended for non-Hodgkin's lymphoma.
Funding Status:
IPO
Headquarters:
Seattle, Washington, United States
Founded Date:
1991
Employee Number:
11-50
Estimated Revenue:
$1M to $10M
Industry:
Biotechnology
Investor Type:
For Profit